MHK
42
-3
EFX
69
-6
CMG
56
2
STI
12
2
ABBV
53
-4
PNW
66
-3
BWA
44
3
PRGO
48
-2
MCO
75
-2
FRT
43
-15
AIG
53
2
YUM
40
-5
THC
58
-4
T
60
-3
TEL
63
2
SLB
50
4
CHK
27
7
MTCH
44
4
SIG
60
2
AMG
41
3
MHK
42
-3
EFX
69
-6
CMG
56
2
STI
12
2
ABBV
53
-4
PNW
66
-3
BWA
44
3
PRGO
48
-2
MCO
75
-2
FRT
43
-15
AIG
53
2
YUM
40
-5
THC
58
-4
T
60
-3
TEL
63
2
SLB
50
4
CHK
27
7
MTCH
44
4
SIG
60
2
AMG
41
3
Financhill
Back

VYNE Therapeutics Quote, Financials, Valuation and Earnings

Free 23-page book shares my #1 indicator to use

Here's the 23-page free book.
Sell
22

VYNE
VYNE Therapeutics

Last Price:
1.89
Seasonality Move:
-14.98%

7 Day Trial

ALL ACCESS PASS

$ 7

How this hedge fund manager trades weekly options

Claim your free training on trading weekly options

VYNE Therapeutics Price Quote

$1.89
+0.06 (+3.28%)
(Updated: September 18, 2024 at 6:55 PM ET)

VYNE Therapeutics Key Stats

Sell
22
VYNE Therapeutics (VYNE) is a Sell
Day range:
$1.83 - $1.89
52-week range:
$1.57 - $4.48
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
96.53
P/B ratio:
0.36%
Volume:
10.8K
Avg. volume:
39.6K
1-year change:
-52.47%
Market cap:
$27M
Revenue:
$424K
EPS:
$-2.82

How Much Does VYNE Therapeutics Make?

Is VYNE Therapeutics Growing As A Company?

  • What Is VYNE Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.47%
  • What Is VYNE Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

VYNE Therapeutics Stock Price Performance

  • Did VYNE Therapeutics Stock Go Up Last Month?
    VYNE Therapeutics share price went down by -1.61% last month
  • Did VYNE's Share Price Rise Over The Last Year?
    VYNE share price fell by -52.47% over the past 1 year

What Is VYNE Therapeutics 52-Week High & Low?

VYNE Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy VYNE Therapeutics?

  • How Much Debt Does VYNE Therapeutics Have?
    Total long term debt quarterly is $0
  • How Much Cash Does VYNE Therapeutics Have?
    Cash and short term investments quarterly total is $78.1M
  • What Is VYNE Therapeutics’s Book Value Per Share?
    Book value per share is 5.15

Is VYNE Therapeutics Cash Flow Positive?

  • What Is VYNE Cash Flow From Operations?
    Cash flow from operations (TTM) is -$26.8M
  • What Is VYNE Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $82.6M
  • What Is VYNE Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$46.9M

VYNE Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    VYNE return on invested capital is -51.55%
  • What Is VYNE Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -44.39%
  • What Is VYNE Return On Equity?
    ROE is a measure of profitability and is -51.55%

VYNE Therapeutics Earnings Date & Stock Price

VYNE Therapeutics Competitors

  • Who Are VYNE Therapeutics's Competitors?
    Below is a list of companies who compete with VYNE Therapeutics or are related in some way:
    • iBio Inc (IBIO)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Oragenics Inc (OGEN)
    • Palatin Technologies Inc (PTN)
    • Theriva Biologics Inc (TOVX)

VYNE Therapeutics Dividend Yield

VYNE Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 0%
Revenue: 46.67% -2%

Analyst Recommendations

Buy Recommendations: 2
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 5.58
Upside from Last Price: 205.1%

Major Shareholders

  • How many VYNE shares are owned by institutional investors?
    9.6M VYNE shares are owned by institutional investors
  • How many VYNE shares are owned by insiders?
    2.3M VYNE shares are owned by insiders